Table 3

Pneumococcal serotypes causing invasive infections among adults 18–49 years of age with and without asthma, Finland, 1995–2002

	n (%)
	Asthma	No asthma	Total
	N=81 (7.7)	N=975 (92.3)	N=1056
Serotypes covered in vaccine formulations
7-valent PCV	44 (54.3)	468 (48.0)	512 (48.5)
10-valent PCV	59 (72.8)	610 (62.6)	669 (63.3)
13-valent PCV	64 (79.0)	740 (75.9)	804 (76.1)
23-valent PPV^*	78 (96.3)	903 (92.6)	981 (92.9)
23-valent PPV^†	73 (90.1)	855 (87.7)	928 (87.9)

↵* All serogroups included in the PPV23 vaccine.
↵† Not including serogroups 10, 11, 12, 15, 17 and 33 which were not serotyped. During 1995–1999, serogroups 10, 11, 12, 15, 17 and 33 were not identified to type level; during 2000–2002, serogroups 11, 12 and 15 were identified to type level.